Russell Matthew R, Blais Benjamin, Nia Nima, Levi Daniel S
Division of Cardiology, Department of Pediatrics, UCLA Mattel Children's Hospital, Los Angeles, CA, USA.
Department of Bioengineering, UCLA Samueli School of Engineering, UCLA, Los Angeles, CA, USA.
Pediatr Cardiol. 2020 Mar;41(3):522-538. doi: 10.1007/s00246-020-02335-w. Epub 2020 Mar 20.
Congenital interventional cardiology has seen rapid growth in recent decades due to the expansion of available medical devices. Percutaneous interventions have become standard of care for many common congenital conditions. Unfortunately, patients with congenital heart disease often require multiple interventions throughout their lifespan. The availability of transcatheter devices that are biodegradable, biocompatible, durable, scalable, and can be delivered in the smallest sized patients will rely on continued advances in engineering. The development pipeline for these devices will require contributions of many individuals in academia and industry including experts in material science and tissue engineering. Advances in tissue engineering, bioresorbable technology, and even new nanotechnologies and nitinol fabrication techniques which may have an impact on the field of transcatheter congenital device in the next decade are summarized in this review. This review highlights recent advances in the engineering of transcatheter-based therapies and discusses future opportunities for engineering of transcatheter devices.
近几十年来,由于可用医疗设备的扩展,先天性介入心脏病学发展迅速。经皮介入已成为许多常见先天性疾病的标准治疗方法。不幸的是,先天性心脏病患者在其一生中往往需要多次介入治疗。可生物降解、生物相容、耐用、可扩展且能用于最小体型患者的经导管设备的可用性将依赖于工程学的持续进步。这些设备的研发流程将需要学术界和产业界许多人的贡献,包括材料科学和组织工程方面的专家。本文综述了组织工程、生物可吸收技术,甚至可能在未来十年对经导管先天性器械领域产生影响的新纳米技术和镍钛诺制造技术的进展。本综述重点介绍了基于导管治疗的工程学最新进展,并讨论了经导管设备工程学的未来机遇。